Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 2014-2024
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.2014
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.2014
Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy
Jie-Yi Zhao, Xiao-Yu Wang, Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Qing-Qing Tang, Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Yu-Ting Luo, Shu-Min Wang, Xiao-Rui Zhu, West China Medical School, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Zhao JY and Wang XY designed the research and wrote the manuscript; Tang QQ and Luo YT analyzed the data; Wang SM and Zhu XR performed data extraction; all authors have read and approved the final version.
Institutional review board statement: This study was reviewed and approved by the West China hospital, Sichuan University Institutional Review Board, Approval No. 2020.18.
Informed consent statement: The requirement for patients’ informed consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: All author reports no conflict of interest.
Data sharing statement: Anyone who wants the data can connect to the corresponding author (yuxixi1052006@126.com ).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yu Wang, MD, Doctor, Department of Neurosurgery, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu 610041, Sichuan Province, China. yuxixi1052006@126.com
Received: June 8, 2022
Peer-review started: June 8, 2022
First decision: June 23, 2022
Revised: July 6, 2022
Accepted: August 22, 2022
Article in press: August 22, 2022
Published online: October 15, 2022
Peer-review started: June 8, 2022
First decision: June 23, 2022
Revised: July 6, 2022
Accepted: August 22, 2022
Article in press: August 22, 2022
Published online: October 15, 2022
Core Tip
Core Tip: Tumor microenvironment (TME) combined with neoadjuvant chemotherapy (NCRT) is the standard treatment for resectable stage II/III rectal cancer (RC). Multiple classes of molecular biomarkers have been studied as potential predictors for RC response but there is no sufficient evidence for any of them to be introduced into clinical practice. By retrospectively evaluating clinical stage II/III RC patients undergoing NCRT followed by standard TME, we found that the combination of NCRT carcinoembryonic antigen and carbohydrate antigen 19-9 levels could be a prognostic predictor for clinical stage II/III RC patients receiving NCRT, and the combined indexes had a stronger predictive effect than the index alone.